FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $55.09, for a total transaction of $2,128,457.24. The sale was disclosed in a filing with the SEC, which is accessible through this link.

FibroGen, Inc (FGEN) traded up 7.23% on Wednesday, reaching $60.10. The company had a trading volume of 2,814,138 shares. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $60.15. The company’s market capitalization is $4.28 billion. The company’s 50 day moving average price is $48.38 and its 200-day moving average price is $34.57.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The firm had revenue of $29.00 million for the quarter, compared to analyst estimates of $34.80 million. On average, equities analysts predict that FibroGen, Inc will post ($1.80) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/04/insider-selling-fibrogen-inc-fgen-ceo-sells-38636-shares-of-stock-2.html.

Several institutional investors and hedge funds have recently modified their holdings of FGEN. BlackRock Inc. lifted its stake in shares of FibroGen by 29,724.1% during the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock valued at $109,811,000 after acquiring an additional 4,439,882 shares during the period. FMR LLC lifted its stake in shares of FibroGen by 96.9% during the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after acquiring an additional 1,641,423 shares during the period. EcoR1 Capital LLC lifted its stake in FibroGen by 3,674.1% in the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock valued at $51,210,000 after buying an additional 1,543,448 shares during the period. Janus Henderson Group PLC acquired a new position in FibroGen in the second quarter valued at about $45,633,000. Finally, Vanguard Group Inc. lifted its stake in FibroGen by 15.1% in the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after buying an additional 761,421 shares during the period. 47.49% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently issued reports on FGEN. Mizuho began coverage on FibroGen in a report on Wednesday. They set a “neutral” rating on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 target price on shares of FibroGen in a report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of FibroGen in a report on Tuesday, September 12th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a report on Wednesday, August 9th. Finally, Goldman Sachs Group, Inc. (The) lowered FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price on the stock. in a report on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. FibroGen presently has a consensus rating of “Buy” and a consensus price target of $60.17.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.